Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06617572 | Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel | available | — | — | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT04091295 |
| BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast |
| available |
| — |
| — |
| Aveni FoundationOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT05612191 | Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) | available | — | — | Advenchen Laboratories, LLCINDUSTRY | 0 | Nov 28, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials